

<b>Course title</b> <English>	医薬品の開発と評価 Drug Development, Evaluation and Regulatory Sciences		<b>Affiliated department, Job title, Name</b>	Graduate School of Medicine Professor, KAWAKAMI, KOJI	
<b>Target year</b>	Professional degree students	<b>Number of credits</b>	1	<b>Course offered year/period</b>	2018/Intensive, Second semester
<b>Day/period</b>	Intensive	<b>Class style</b>	Lecture	<b>Language</b>	Japanese and English
<b>[Outline and Purpose of the Course]</b>					
<p>Director and Instructors:            (Director) Koji Kawakami (Professor , Pharmacoeepidemiology), Hiromitsu Shirasawa (MSD, Japan), Ikuo Horii (Cambridge Univ.), Masayoshi Murakami (Foundation for Biomedical Reserch and Innovatuion), Hisashi Urushihara (Keio Univ.), Yoshie Onishi (CreativCeutical), Haruka Yoshimura (MOF)</p> <p>The efficacy and safety of the drug, biologics, and medical devices are evaluated through the drug development process involving preclinical and clinical studies, manufacturing, and post-marketing surveillance. Also, cost/benefit consideration through the comparative effective research is necessary. Fundamental considerations of these issues along with research examples will be discussed.</p>					
<b>[Course Goals]</b>					
To understand idea of the development, evaluation, cost/benefit of medicinal products.					
<b>[Course Schedule and Contents]</b>					
November 21 Regulatory affairs in the globalwide pharmaceutical company (Shirasawa) November 28 Drug development and toxicity/safety (Horii) December 5 Tanslational reserch and industrializatons (Murakami) December 12 Medical real world data and Medicine evaluation (Kawakami) December 19 Postmarketing surveillance (Urushihara) Dcember 26 Pharmacoeconomics and value-based drug pricing (Onishi) January 9 Finance of Japan and healthcare (Yoshimura) January 16 Sight visiting of Kobe medical cluster					
<b>[Class requirement]</b>					
You must take this course along with the course H109 “ Drug policy and regulation ” otherwise the entire grasp of the drug research, development, and regulations will not be achieved.					
<b>[Method, Point of view, and Attainment levels of Evaluation]</b>					
Participation (50%) and report (50%)					
<b>[Textbook]</b>					
Suggested reading: Hartzema, A.C. et al., ed. Pharmacoeepidemiology: An Introduction 3rd ed., Harvey Whitney. 1998. Saeko Yasuo et al. Invitation to new drug development. Kyoritsu Press, 2006 (Japanese). Koji Kawakami (ed.) <u>The Beginner ’ s guidance to the clinical research and development. Medical Do, 2010</u>					
Continue to 医薬品の開発と評価(2)					

## 医薬品の開発と評価(2)

(Japanese).

### [Reference books, etc.]

( Reference books )

### [Regarding studies out of class (preparation and review)]

Preparation in advance and review after lecture

### ( Others (office hour, etc.) )

Koji Kawakami ( 3F, Bldg G ) appointment required by email.

e-mail: kawakami.koji.4e@kyoto-u.ac.jp

intermediate

\*Please visit KULASIS to find out about office hours.